Pediatric Exclusivity Revenues for Cancer Drugs
This cohort study calculates the cost of pediatric trials and the value of pediatric exclusivity for select cancer drugs.
Authors
- Douglas M. Hawkins (ORCID: https://orcid.org/0000-0002-5983-921X)
- Liam Bendicksen (ORCID: https://orcid.org/0000-0002-0355-0716)
- Ameet Sarpatwari (ORCID: https://orcid.org/0000-0001-5043-6206)
- Lia Gore (ORCID: https://orcid.org/0000-0002-2546-4616)
- Florence T. Bourgeois (ORCID: https://orcid.org/0000-0001-7798-4560)
Institutions
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Seattle Children's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Children's Hospital Colorado (US)
- Center for Cancer and Blood Disorders (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- JAMA Pediatrics
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1001/jamapediatrics.2024.4449
- Citations
- 3
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 3.33